Provided by Tiger Fintech (Singapore) Pte. Ltd.

Sonnet BioTherapeutics Holdings, Inc.

1.36
-0.0600-4.23%
Volume:36.80K
Turnover:49.97K
Market Cap:4.17M
PE:-0.15
High:1.45
Open:1.45
Low:1.33
Close:1.42
Loading ...

Sonnet BioTherapeutics Successfully Completes First Safety Review of SON-1010 in Combination with Trabectedin in Certain Sarcomas

GlobeNewswire
·
26 Mar

Sonnet BioTherapeutics receives notice of allowance for U.S. patent for IL-18

TIPRANKS
·
19 Mar

Sonnet Biotherapeutics Receives Notice of Allowance for U.S. Patent Covering Composition of Matter of Specific Amino Acid Substitutions of Its Il-18 Binding Protein Resistant Variant Protein

THOMSON REUTERS
·
19 Mar

Sonnet BioTherapeutics Receives Notice of Allowance for U.S. Patent Covering Composition of Matter of Specific Amino Acid Substitutions of its IL-18 Binding Protein Resistant Variant Protein

GlobeNewswire
·
19 Mar

Sonnet BioTherapeutics Holdings, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

GlobeNewswire
·
11 Mar

Sonnet BioTherapeutics Presents Compilation of Data Highlighting the Potential of SON-1010 as a Monotherapy or a Combination Therapy to Improve the Treatment of Solid Tumors

GlobeNewswire
·
26 Feb

BRIEF-Sonnet Biotherapeutics' Proprietary ADC Platform Available For Drug Discovery Partnerships

Reuters
·
19 Feb

Sonnet Biotherapeutics Announces That Its Proprietary Antibody Drug Conjugate (ADC) Platform Is Available for Drug Discovery Partnerships With Potential for Producing Multiple Pipeline Drug Candidates

THOMSON REUTERS
·
19 Feb

Sonnet BioTherapeutics Announces That Its Proprietary Antibody Drug Conjugate (ADC) Platform is Available for Drug Discovery Partnerships with Potential for Producing Multiple Pipeline Drug Candidates

GlobeNewswire
·
19 Feb

Sonnet BioTherapeutics Selected for Poster Presentation at the 2025 AACR IO Conference

GlobeNewswire
·
18 Feb

Sonnet Biotherapeutics Holdings Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
14 Feb

Sonnet BioTherapeutics appoints McAndrew as Chief Business Officer

TIPRANKS
·
13 Feb

BRIEF-Sonnet Biotherapeutics Appoints Stephen Mcandrew As Chief Business Officer

Reuters
·
13 Feb

Sonnet Biotherapeutics Appoints Stephen Mcandrew, Ph.d. as Chief Business Officer

THOMSON REUTERS
·
13 Feb

Sonnet BioTherapeutics Appoints Stephen McAndrew, Ph.D. as Chief Business Officer

GlobeNewswire
·
13 Feb

Sonnet BioTherapeutics Q1 EPS $(1.56) Misses $(1.39) Estimate

Benzinga
·
13 Feb

Sonnet Biotherapeutics Holdings Inc Qtrly Loss per Share $1.56

THOMSON REUTERS
·
13 Feb

Sonnet Biotherapeutics Holdings Inc: Jay Cross Resigns as CFO, Effective Feb 21, 2025

THOMSON REUTERS
·
13 Feb

Sonnet BioTherapeutics Provides Fiscal Year 2025 First Quarter Business and Earnings Update

GlobeNewswire
·
13 Feb

Sonnet Biotherapeutics Holdings Inc expected to post a loss of $1.39 a share - Earnings Preview

Reuters
·
10 Feb